rs2144908 — HNF4A HNF4A P2 Block rs2144908

Intronic HNF4A P2 promoter haplotype tag variant; carriers have modestly impaired glucose-stimulated insulin secretion and elevated type 2 diabetes susceptibility

See your personal result for HNF4A

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

HNF4A P2 rs2144908 — Tuning the Beta-Cell Master Switch

HNF4A11 HNF4A
Hepatocyte Nuclear Factor 4 Alpha — a nuclear receptor transcription factor essential for pancreatic beta-cell identity, hepatic lipid metabolism, and glucose homeostasis is one of the most important metabolic transcription factors in the body. Unlike many diabetes genes that act through a single pathway, HNF4A controls the expression of dozens of downstream targets including GLUT2 (glucose transporter), glucokinase, mitochondrial enzymes, and other transcription factors such as HNF1A. Loss-of-function mutations in HNF4A cause MODY122 MODY1
Maturity-Onset Diabetes of the Young type 1 — a monogenic, autosomal dominant diabetes caused by HNF4A haploinsufficiency in beta cells; characterised by early-onset non-insulin-dependent diabetes in lean individuals.

rs2144908 sits in an intron of HNF4A on the GRCh38 plus strand (chr20:44,357,077) and is one of four variants — along with rs4810424, rs1884613, and rs1884614 — that define the common HNF4A P2 promoter haplotype block. This block tags regulatory variation in the P2 promoter, the alternative upstream promoter that drives HNF4A expression specifically in pancreatic beta cells (and, to a lesser extent, fetal liver).

The Mechanism

The HNF4A gene has two functional promoters. The P1 promoter is active in adult liver and drives the HNF4A1–6 isoform family. The P2 promoter is active in pancreatic beta cells and drives the HNF4A7–12 family — also known as the "fetal" isoforms — which persist into adulthood in the pancreas. The P2 promoter is controlled partly by HNF1A, creating a transcriptional feedback circuit: HNF4A (P2 isoform) → HNF1A → HNF4A, which is disrupted by variants in either gene, as confirmed by Kind et al. 2024 (Diabetes)33 Kind et al. 2024 (Diabetes)
HNF-1A mediates HNF4A P2 promoter regulation; P2-linked mutations impair glucose-stimulated insulin secretion in beta cells. Diabetes, 2024.

The A allele at rs2144908 tags a P2 haplotype associated with mildly reduced P2 promoter activity in beta cells — or altered responsiveness of the promoter to transcriptional activators. The consequence is reduced HNF4A protein in beta cells, which impairs the cell's ability to ramp up insulin secretion in response to rising blood glucose. In the adult liver, the same P2 isoform becomes aberrantly re-expressed in type 2 diabetes44 aberrantly re-expressed in type 2 diabetes
Chronically elevated P2 isoform in diabetic liver promotes excess hepatic glucose production through a glucagon→TET3→FOXA2→P2 demethylation axis, compounding hyperglycemia on top of impaired insulin secretion. The A allele at rs2144908 thus implicates both pancreatic and hepatic arms of glucose dysregulation.

The Evidence

The HNF4A P2 haplotype was originally identified in Finnish and Ashkenazi populations in 2004, and rs2144908 was one of the four SNPs used by Weedon et al. 200455 Weedon et al. 2004
Common variants of the hepatocyte nuclear factor-4alpha P2 promoter are associated with type 2 diabetes in the U.K. population. Diabetes, 2004 to tag the risk haplotype in 5,256 UK subjects, where the risk haplotype carried an OR of 1.15 (95% CI 1.02–1.33, P=0.02). A 2007 Norwegian population study and meta-analysis by Johansson et al.66 Johansson et al.
Studies in 3,523 Norwegians and meta-analysis in 11,571 subjects indicate HNF4A P2 region variants are associated with type 2 diabetes in Scandinavians. Diabetes, 2007 reported rs2144908 itself with OR 1.21 (95% CI 1.05–1.38) in the Norwegian cohort, and a Scandinavian-restricted meta-analysis OR of 1.14 (1.06–1.23, P=0.0004) for the lead P2 tag SNP rs1884613.

In North Indian subjects, Chavali et al. 201177 Chavali et al. 2011
Association of variants in genes involved in pancreatic beta-cell development and function with type 2 diabetes in North Indians. J Hum Genet, 2011 found rs2144908 significantly associated with T2D (OR 1.37, 95% CI 1.20–1.57, P=6.0×10⁻⁶) in 2,025 subjects, with the effect notably stronger in normal-weight individuals — consistent with a primary beta-cell deficiency mechanism rather than an obesity-driven insulin resistance pathway.

The A allele is the minor allele in Europeans (~17%) and Africans (~11%), but has much higher frequency in East Asians (~46%) and South Asians (~27%). Effect sizes have been inconsistent across populations, partly because the causal functional variant within the P2 haplotype block has not been definitively identified, and the LD pattern between rs2144908 and the true causal variant differs by ancestry.

Practical Actions

The A allele at rs2144908 modestly impairs glucose-stimulated insulin secretion through reduced HNF4A activity in beta cells. For heterozygous AG carriers (the most common at-risk genotype), the risk elevation per allele is modest (OR ~1.15–1.21), equivalent to roughly a 15–20% increase in relative risk for type 2 diabetes. This is not alarming in isolation, but becomes clinically meaningful when combined with additional T2D risk factors (family history, excess weight, sedentary lifestyle, other T2D-associated variants). Periodic monitoring of fasting glucose and HbA1c is the core intervention, since early detection of prediabetes enables lifestyle changes that can prevent progression. Reducing postprandial glucose spikes through low-glycemic- index carbohydrate choices directly compensates for reduced beta-cell secretory reserve.

For homozygous AA carriers, who carry both copies of the risk haplotype, an oral glucose tolerance test (OGTT) provides more sensitive detection of beta-cell secretory impairment than fasting glucose alone, since the OGTT specifically challenges the glucose-stimulated insulin secretion pathway disrupted by this locus.

Interactions

rs2144908 is in strong linkage disequilibrium (D' > 0.97, r² > 0.90) with rs4810424, rs1884613, rs1884614, and rs6031552 — all of which tag the same P2 haplotype block. These variants do not represent independent risk signals; they capture the same underlying haplotype. Carrying risk alleles at multiple P2 block SNPs does not add cumulative independent risk beyond the haplotype itself.

Functionally, HNF4A and KCNJ11 (rs5219, Kir6.2 E23K) interact: HNF4A is a known transcriptional regulator of the KCNJ11 gene. Qi et al. 200788 Qi et al. 2007
Gene-gene interactions between HNF4A and KCNJ11 in predicting type 2 diabetes in women. Diabet Med, 2007 found significant interactions between HNF4A rs2144908 and KCNJ11 E23K in predicting T2D risk in women (P=0.017), with combined minor allele carriage substantially elevating risk above either variant alone. TCF7L2 rs7903146 (Wnt/incretin pathway) impairs a third independent beta-cell secretory mechanism; carriers of both HNF4A P2 and TCF7L2 risk alleles face compounded beta-cell dysfunction warranting earlier glucose monitoring.

Nutrient Interactions

glucose altered_metabolism
lipids altered_metabolism

Genotype Interpretations

What each possible genotype means for this variant.

GG Reference Genotype Normal

Reference genotype — no HNF4A P2 haplotype risk from this locus

The G allele is the reference allele on the GRCh38 plus strand. The HNF4A P2 promoter haplotype is defined by the A allele at rs2144908 (and co-varying A/C/G alleles at other P2 block SNPs). GG homozygotes are not carriers of this haplotype, meaning their HNF4A P2 promoter activity in beta cells follows the population reference pattern — providing no additional susceptibility to glucose-stimulated insulin secretion impairment from this locus specifically.

Your overall type 2 diabetes risk is determined by the combined effect of many other variants, lifestyle factors, and family history.

AG P2 Haplotype Carrier Intermediate

One copy of the HNF4A P2 risk allele — modest elevation in insulin secretion impairment risk

The A allele at rs2144908 co-segregates with a common HNF4A P2 haplotype that mildly reduces beta-cell P2 promoter activity. The downstream effect is a modest reduction in HNF4A protein levels in the pancreas, impairing the speed and magnitude of glucose-stimulated insulin release. In the Norwegian meta-analysis (Johansson 2007), rs2144908 itself carried OR 1.21 (95% CI 1.05–1.38) in the Norwegian sub-cohort; across the Scandinavian meta-analysis, the P2 haplotype OR was 1.14 per allele. In North Indians (Chavali 2011), the association was stronger (OR 1.37), particularly in lean subjects, supporting a primary insulin secretory mechanism.

The P2 haplotype is an additive risk signal — one A allele confers roughly half the risk elevation of two copies. In absolute terms, this is a modest effect that is most clinically significant when other T2D risk factors are present.

AA P2 Haplotype Homozygote High Risk

Two copies of the HNF4A P2 risk allele — elevated beta-cell impairment and diabetes susceptibility

Homozygous AA individuals carry two full copies of the HNF4A P2 risk haplotype. Based on the additive model OR of 1.14–1.37 per allele documented across studies, homozygotes accumulate the full two-allele risk increment. The North Indian study (Chavali 2011) specifically showed OR 1.37 per allele at this locus in lean subjects, supporting a dose-dependent impairment of beta-cell secretory function rather than an obesity-mediated pathway.

In the hepatic arm of this variant's biology, the glucagon–TET3–FOXA2 axis (Li et al. 2020 (Nat Commun)) can aberrantly re-activate the P2 isoform in the liver under metabolic stress, amplifying hepatic glucose overproduction on top of reduced insulin release — a dual hit on glucose homeostasis that homozygotes would be most susceptible to as they age and accumulate metabolic stress.

An oral glucose tolerance test (OGTT) is the most appropriate screening tool for this genotype because it directly measures glucose-stimulated insulin secretion — the precise pathway impaired by this locus — and can detect subtle beta-cell dysfunction before fasting glucose or HbA1c become abnormal.